NEW YORK, July 17, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Inspire Medical Systems, Inc. (NYSE: INSP) on behalf of long-term stockholders following a class action complaint that was filed against Inspire Medical on December 22, 2023 with a Class Period from May 3, 2023 to November 7, 2023. Our investigation concerns whether the board of directors of Inspire Medical have breached their fiduciary dutie ...

Company Overview - Inspire Medical Systems Inc. has issued a recall for its Inspire IV Implantable Pulse Generator (IPG) Model 3028 due to a critical manufacturing defect that can lead to electrical leakage, potentially causing severe health consequences [1][14] - The recall has been classified by the FDA as the most serious type, indicating the urgency and severity of the issue [1] Impact of the Recall - The defect in the device can result in stimulation below normal therapeutic levels, early battery depletion, and inconsistent or inappropriate stimulation, which necessitates immediate identification and correction to prevent serious health risks [3] - Following the recall announcement, shares of Inspire Medical declined by 3.3% to close at $131.44 [8] - Year-to-date, shares of Inspire Medical have decreased by 35.4%, contrasting with the industry's decline of 19.5% [10] Industry Prospects - The market for implantable pulse generators is experiencing significant growth, projected to reach $188.76 billion by 2030, with a compound annual growth rate (CAGR) of 8.6% from a valuation of $118.57 billion in 2023 [16] - Advances in medical technology and the rising incidence of neurological illnesses and chronic pain are driving the demand for smaller, more effective devices with improved battery life and wireless communication capabilities [9] Financial Performance - In the first quarter of 2024, the company reported a 25% year-over-year increase in U.S. revenues, attributed to increased market penetration of Inspire therapy [15]

There have been no reported injuries. There have been no reports of death. The IPG works with external programmers that allow the physician to set and adjust the therapy parameters and the patient to control the therapy's activation and intensity. Loading... The FDA has labeled a recall of Inspire Medical Systems, Inc.'s INSP nerve-stimulating implant for obstructive sleep apnea as Class I, the most serious kind. Inspire Medical Systems is recalling Inspire IV Implantable Pulse Generator (IPG) Model 3028 du ...

Company Overview - Inspire Medical Systems is a medical technology company focused on developing and commercializing innovative, minimally invasive solutions for patients with obstructive sleep apnea [3]. Financial Results Announcement - Inspire will release its financial results for the second quarter of 2024 after the close of trading on Tuesday, August 6 [4]. - A conference call will be hosted by Inspire's management team at 5:00 p.m. Eastern Time to discuss the financial results and recent business developments [4]. Conference Call Details - Investors can register for the conference call, and an email will be sent with dial-in details and a unique access code [1]. - A replay of the call will be available on the Company's Investor Relations website approximately two hours after the event and archived for two weeks [2]. - A webcast of the call will also be accessible via the Investor Relations page of the Inspire website [5].

MINNEAPOLIS, July 02, 2024 (GLOBE NEWSWIRE) -- Inspire Medical Systems, Inc. (NYSE: INSP) (Inspire) will release financial results for the second quarter 2024 after the close of trading on Tuesday, August 6. Inspire's management team will host a corresponding conference call beginning at 5:00 p.m. Eastern Time to discuss the financial results and recent business developments. Following the call, a replay will be available on the Company's Investor Relations website approximately two hours after the event an ...

A month has gone by since the last earnings report for Inspire Medical Systems (INSP) . Shares have lost about 7.3% in that time frame, underperforming the S&P 500. Will the recent negative trend continue leading up to its next earnings release, or is Inspire due for a breakout? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at the most recent earnings report in order to get a better handle on the important drivers. Inspire Medical Q1 Earnings Beat, Gross Mar ...

Company Overview - Inspire Medical Systems, Inc. is a medical technology company focused on developing and commercializing innovative, minimally invasive solutions for patients with obstructive sleep apnea [3] - The company's proprietary Inspire therapy is the first and only FDA-approved neurostimulation technology that provides a safe and effective treatment for moderate to severe obstructive sleep apnea [3] Upcoming Events - Inspire's management team will present at the Truist Securities Medtech Conference on June 18, 2024, at 10:40 a.m. Eastern Time [1] - The presentation will be accessible via a live webcast [1] - A replay of the presentation will be available for two weeks following the event in the Event Archive section of Inspire's Investor website [2]

Inspire Medical Systems, Inc. (INSP) is well-poised for growth in the coming quarters, courtesy of its focus on research and development (R&D). The optimism led by a solid first-quarter 2024 performance and its global presence are expected to contribute further. However, concerns regarding overdependence on the Inspire system and a competitive landscape prevail. Over the past year, this Zacks Rank #3 (Hold) stock has lost 49.3% compared with the 25.3% decline of the industry. The S&P 500 has witnessed 26.7% ...

Inspire Medical Systems, Inc. (INSP) delivered a loss per share of 34 cents in first-quarter 2024, narrower than the year-ago period’s loss of 53 cents per share. The metric was also narrower than the Zacks Consensus Estimate of a loss of 63 cents per share.Revenues in DetailInspire Medical registered revenues of $164 million in the first quarter, up 28.2% year over year. The figure beat the Zacks Consensus Estimate by 1.5%.Per management, the top-line growth was driven by increased market penetration in ex ...

For the quarter ended March 2024, Inspire Medical Systems (INSP) reported revenue of $164.01 million, up 28.2% over the same period last year. EPS came in at -$0.34, compared to -$0.53 in the year-ago quarter.The reported revenue compares to the Zacks Consensus Estimate of $161.63 million, representing a surprise of +1.47%. The company delivered an EPS surprise of +46.03%, with the consensus EPS estimate being -$0.63.While investors scrutinize revenue and earnings changes year-over-year and how they compare ...